


### Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

#### Listing of Claims

1-15. (cancelled)

16. (new) A method of treating epilepsy comprising administering to a subject in need of such treatment a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula



characterized by characteristic lines at interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å and 2.81 Å, as determined by means of an X-ray powder pattern.

17. (new) A method according to Claim 16 comprising administering a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by an X-ray powder pattern having the following characteristic lines at interplanar spacings (d values) of 10.9 Å (weak), 10.5 Å (medium), 6.6 Å (weak), 5.63 Å (weak), 5.25 Å (weak), 5.14 Å (medium), 4.94 Å (weak), 4.84 Å (very strong), 4.55 Å (strong), 4.42 Å (very weak), 4.34 Å (medium), 4.23 Å (very weak), 4.16 Å (weak), 4.07 Å (medium), 4.01 Å (weak), 3.68 Å (very weak), 3.64 Å (very weak), 3.60 Å (weak), 3.56 Å (weak), 3.51 Å (medium), 3.48 Å (medium), 3.38 Å (very weak), 3.25 Å (strong), 3.19 Å (medium), 3.15 Å (medium), 3.11 Å (weak), 3.07 Å (medium), 2.93 Å (very weak), 2.87 Å (very weak), 2.81 Å (medium), 2.76 Å (weak), 2.73 Å (very weak), 2.68 Å (weak), 2.62 Å (very weak), 2.53 Å (weak), 2.43 Å (weak) and 2.40 Å (very weak).

18. (new) A method according to Claim 16 comprising administering a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by absorption bands at 3412 cm<sup>-1</sup> and 3092 cm<sup>-1</sup> in the FT-IR spectrum (KBr pellet-transmission method).

19. (new) A method according to Claim 18 comprising administering a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by the following absorption bands in the FT-IR spectrum (KBr pellet - transmission method): 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640  $\text{cm}^{-1}$ .


20. (new) A method according to Claim 16 comprising administering a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by an endothermic peak in the range from 230°C to 260°C, the peak temperature being 239-245°C and the endothermic signal being 209 J/g  $\pm$  10 J/g.

21. (new) A method according to Claim 16 comprising administering a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by an absorption band at 1080  $\text{cm}^{-1}$  in the FT-Raman spectrum.

22. (new) A method according to Claim 21 comprising administering a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by the following absorption bands in the FT-Raman spectrum (powder - reflection method 180°): 3093, 2972, 1628, 1614, 1558, 1465, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368  $\text{cm}^{-1}$ .

23. (new) A method according to Claim 16 comprising administering a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide in essentially pure form.

24. (new) A method of treating epilepsy comprising administering to a subject in need of such treatment a therapeutically effective amount of crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula



characterized by characteristic lines at interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å and 2.81 Å, identical to crystal modification A as determined by means of an X-ray powder pattern, but has smaller line spacings with otherwise predominantly identical lines or bands.

25. (new) A method according to Claim 24 comprising administering a therapeutically effective amount of crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by line spacings, slightly smaller compared to crystal modification A, between the pairs of lines at interplanar spacings 3.68 Å and 3.64 Å, 3.51 Å and 3.48 Å, and 3.19 Å and 3.15 Å.

26. (new) A method according to Claim 24 comprising administering a therapeutically effective amount of crystal modification A' of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide in essentially pure form.